The reason for the absence of any media coverage of the NYAS presentation is simple.
The full Public Relations offensive is well under way, but all news outlets are under the same embargo that prevents the company from speaking about the results before the article is officially certified by the scientific journal as 'Peer Reviewed'. That's what all the newspapers and the company are waiting for. That 'certification' is No Small Thing.
The 2018 JTM Blended analysis was the top story on the BBC evening news (save for a minor terrorist incident). The edited 'package' contained interviews with doctors, patients and analysis from their science correspondent. I worked for the BBC for a time and the level of production of the piece suggested something that would've taken weeks to independently research, organise, shoot, edit and store in anticipation of the embargo lift. It came out the same evening as the article, and would've been briefed and produced long in advance.
The same thing is happening here. That's why there's no incidental coverage of the New York presentation. The news outlets already have the Big Story and are waiting for the green light.
DCVax is the biggest story in medicine (if not science) this year. The fact that no one reported on the presentation is proof to me that the media pump is being primed.
Added to the beauty of the science is the sheer human DRAMA of this whole caper. All the twists and turns, reversals and disappointments, are manna from heaven for bored science and finance journalists. It makes for a great narrative and we mustn't underestimate the power of that in our climate. Big Pharma, Evil Hedge Funds, David, Goliath, a Cancer Vaccine (surely Magic Beans...sounds like the water engine, no?...Ack! No! Look at the numbers!).
All sorts of curtains will rise and fall over the next few months.
Market Data 
Markets 
AI
